# 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

> **NCT03849118** · PHASE3 · COMPLETED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 300 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** 89Zr-girentuximab

## Key facts

- **NCT ID:** NCT03849118
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-15
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-11-07
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03849118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03849118, "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03849118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*